Low Dose Naltrexone (LDN) Provides Surprising Pain Relief (News)

Low Dose Naltrexone (LDN) Provides Surprising Pain Relief The People’s Pharmacy 18 August 2022 https://www.peoplespharmacy.com/articles/low-dose-naltrexone-ldn-provides-surprising-pain-relief People who suffer with severe chronic pain often face a difficult dilemma. Opioids aren’t considered appropriate for long-term use. Physicians and pharmacists may be chastised by their professional organizations if they repeatedly prescribe or dispense such drugs. NSAIDs like diclofenac, ibuprofen, […]

What Is Low-Dose Naltrexone (LDN)? (News)

What Is Low-Dose Naltrexone (LDN)? Lifespan.io 29 April 2022 https://www.lifespan.io/topic/what-is-low-dose-naltrexone-ldn/ LDN, through its action on MOR, can theoretically reduce pain, anxiety, depression, and attention difficulties, improve motivation, and possibly contribute to better weight control, sleep, libido, and energy. In combination with LDN’s effects through OGFr, LDN may improve conditions like IBS, Crohn’s disease, and other […]

Asher Goldstein, MD – LDN Radio Show 2022 (LDN; low dose naltrexone)

  Asher Goldstein, MD – LDN Radio Show 2022 (LDN; low dose naltrexone) SUMMARY Over the past 2.5 years that Dr. Goldstein has been prescribing low-dose naltrexone (LDN), he has shifted to a much lower and slower titration pack. He uses it for many applications in addition to pain, such as fibromyalgia, Crohn’s, rheumatoid arthritis, […]

Can Low-Dose Naltrexone Offer Pain Relief? (News)

Can Low-Dose Naltrexone Offer Pain Relief? MedPage Today 27 June 2022 https://www.medpagetoday.com/opinion/pain-points/99457 The most intriguing and encouraging finding is that so-called neuropathic pain may benefit even more from LDN than the so-called nociceptive or inflammatory pain states that it has been directed at over the past 20 years. Growing evidence suggests TLR-4 is involved in […]

… Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia (News)

Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia GuruFocus 20 June 2022 https://www.gurufocus.com/news/1770836/scilex-a-sorrento-company-highlights-safety-data-from-phase-1-trial-of-sp104-a-proprietary-low-dose-naltrexone-for-fibromyalgia SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM). There are an estimated 10 million FM patients […]